In this section, we aim to present clinical research data that support a potentially prognostic, as well as predictive role for PD-L1 expression in gastric cancer, and finally present up to date results from large scale, phase III clinical trials, that have investigated the efficacy of PD-1/PD-L1 inhibitors in clinical practice. The gene discussed is PDCD1; the disease is gastric cancer.